Novartis AG
NVS Real Time Price USD$NVS is featured in our Tom Carper and Shelley Moore Capito strategies.
All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: System and method for determining biometric properties of an eye May. 16, 2017
-
Patent Title: Resolution enhancement of oct images during vitreoretinal surgery May. 16, 2017
-
Patent Title: Magnification in ophthalmic procedures and associated devices, systems, and methods May. 09, 2017
-
Patent Title: Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives May. 09, 2017
-
Patent Title: Oct image modification May. 02, 2017
-
Patent Title: Polymerizable polysiloxanes with hydrophilic substituents May. 02, 2017
-
Patent Title: Isoxazoline hydroxamic acid derivatives as lpxc inhibitors May. 02, 2017
-
Patent Title: Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine May. 02, 2017
-
Patent Title: Equipment and methods used in folding and implanting foldable lenses in the eye May. 02, 2017
-
Patent Title: Autotaxin inhibitors Apr. 25, 2017
-
Patent Title: Methods for identification of sites for igg conjugation Apr. 25, 2017
-
Patent Title: Compounds and compositions as inhibitors of mek Apr. 25, 2017
-
Patent Title: Pump roller head with pivoting rollers and spring arms Apr. 18, 2017
-
Patent Title: Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues Apr. 18, 2017
-
Patent Title: Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease Apr. 18, 2017
-
Patent Title: Heterocyclic compounds and methods of their use Apr. 18, 2017
-
Patent Title: Heterocyclic compounds and methods for their use Apr. 18, 2017
-
Patent Title: Carbamate/urea derivatives Apr. 18, 2017
-
Patent Title: Process for preparing intermediates useful in the manufacture of nep inhibitors Apr. 18, 2017
-
Patent Title: Method for making contact lenses Apr. 18, 2017
-
Patent Title: Process for manufacturing an ophthalmic lens Apr. 18, 2017
-
Patent Title: Formulation comprising benzothiazolone compound Apr. 18, 2017
-
Patent Title: Pharmaceutical composition Apr. 18, 2017
-
Patent Title: Ophthalmic lenses with oxygen-generating elements therein Apr. 11, 2017
-
Patent Title: Multi-port vitrectomy probe with dual cutting edges Apr. 11, 2017
-
Patent Title: Extended wear ophthalmic lens Apr. 04, 2017
-
Patent Title: Forward flow impeding infusion sleeve and associated systems and methods Apr. 04, 2017
-
Patent Title: Forward scanning optical probes Mar. 28, 2017
-
Patent Title: Antibody molecules to tim-3 and uses thereof Mar. 28, 2017
-
Patent Title: Ip receptor agonist heterocyclic compounds Mar. 28, 2017
-
Patent Title: Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof Mar. 28, 2017
-
Patent Title: Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension Mar. 28, 2017
-
Patent Title: Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester Mar. 28, 2017
-
Patent Title: Substituted aminobutyric derivatives as neprilysin inhibitors Mar. 28, 2017
-
Patent Title: Remote magnetic driven flow system Mar. 28, 2017
-
Patent Title: Chemical process for preparing spiroindolones and intermediates thereof Mar. 21, 2017
-
Patent Title: Marker-based tool tracking Mar. 21, 2017
-
Patent Title: Myopia control means Mar. 14, 2017
-
Patent Title: Polymorphous forms iii and iv of n-benzoyl-staurosporine Mar. 14, 2017
-
Patent Title: Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Mar. 14, 2017
-
Patent Title: Compositions and methods for disinfecting and cleaning contact lenses Mar. 14, 2017
-
Patent Title: Site-specific labeling methods and molecules produced thereby Mar. 07, 2017
-
Patent Title: Ocular implant with hydrogel expansion capabilities Mar. 07, 2017
-
Patent Title: Vitrectomy probe with adjustable cutter port size Mar. 07, 2017
-
Patent Title: Ophthalmic surgical microscope with adaptive optics for optical wavefront compensation Mar. 07, 2017
-
Patent Title: Power source for an accommodating intraocular lens Feb. 28, 2017
-
Patent Title: Exogenous internal positive control Feb. 28, 2017
-
Patent Title: Triazolopyrimidine compounds and uses thereof Feb. 28, 2017
-
Patent Title: Compounds that expand hematopoietic stem cells Feb. 28, 2017
-
Patent Title: Surgical cassette with compliant clamping zone Feb. 28, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.